Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Post by bionicjoeon May 10, 2019 2:09pm
141 Views
Post# 29735273

What we are seeing

What we are seeing The market has been nervous anytime we get near a major cannabis company's reporting date and it's no exception with ACB. It's been that way for a couple of weeks now as investors don't want to be caught with their pants down should the quarterly miss by a large margin. Its not that anybody questions whether Aurora will be one of the dominant producers and sellers once the supply chain issues are resolved. It's more that for the moment with no LP as of yet reporting knock the socks off type quarterlies to say the least, the market isn't expecting much next week from ACB. Add to that the lack of even half credible rumors about a partnership and let's not forget Trump flexing his ego and you get for a pretty lacklustre preamble for what will likely be a so-so financial statement. The Wall Street Journal is predicting a concensus of $79.7M in revenue. For longs that have had to edure the the taunts from the boiler room crowd it will only make victory that much sweeter once ACB starts demonstrating to the market what it is capable of in real terms.
Bullboard Posts